For the first time since Australia rescheduled MDMA and psilocybin, a shipment of the compounds has been made to the country to be used under the...
Enveric Biosciences has confirmed it has completed the manufacture of its lead drug candidate – EB-373 – a New Chemical Entity (NCE) designed as a next-generation...
PharmAla Biotech Holdings has announced that it has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia.
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.